Aims & Scope
In-vitro In-vivo In-silico Journal (IIIJ) publishes rigorous research integrating experimental and computational methodologies across pharmaceutical sciences, drug development, and translational biomedicine. We prioritize studies that bridge in-vitro assays, in-vivo models, and in-silico predictions to advance therapeutic innovation and mechanistic understanding.
Drug Discovery
Computational Pharmacology
Translational Research
Preclinical Models
Systems Biology
Scope Boundary: We do NOT consider purely clinical studies without experimental validation, standalone observational research, or theoretical models lacking empirical support.
Core Research Domains
Tier 1: Priority AreasComputational Drug Discovery
- Molecular docking and virtual screening
- Quantitative structure-activity relationship (QSAR) modeling
- Pharmacophore development and validation
- Protein structure prediction and homology modeling
- Network pharmacology and polypharmacology
- AI-driven drug design and deep learning applications
Typical Fit:
Machine learning models predicting kinase inhibitor selectivity validated through in-vitro enzyme assays and in-vivo xenograft studies.
In-Vitro Experimental Systems
- Cell-based assays for drug screening and toxicity
- Organ-on-a-chip and microphysiological systems
- 3D cell culture models and spheroid technology
- High-throughput and high-content screening platforms
- Biomarker discovery and validation
- Drug metabolism and pharmacokinetic studies
Typical Fit:
Liver-on-a-chip model evaluating hepatotoxicity of novel compounds with integrated metabolomics analysis and computational PBPK modeling.
In-Vivo Pharmacology & Toxicology
- Preclinical animal models for disease and therapy
- Pharmacokinetics and pharmacodynamics (PK/PD) studies
- Toxicology screening and safety assessment
- In-vivo imaging and biomarker tracking
- Behavioral and physiological measurements
- Translational efficacy and mechanism studies
Typical Fit:
Mouse model of Alzheimer's disease testing novel tau aggregation inhibitors with PET imaging, cognitive testing, and histopathological validation.
Integrative Systems Pharmacology
- Quantitative systems pharmacology (QSP) modeling
- Multi-scale modeling from molecular to organism level
- Pathway analysis and systems biology approaches
- Pharmacogenomics and precision medicine
- Drug repurposing through computational and experimental integration
- Biomarker-driven therapeutic strategies
Typical Fit:
Systems biology model of cancer metabolism integrating transcriptomics, metabolomics, and in-vitro validation to identify synthetic lethal targets.
Secondary Focus Areas
Tier 2: Cross-Disciplinary & MethodologicalMedicinal Chemistry
- Structure-based drug design
- Chemical synthesis and optimization
- Cheminformatics and compound libraries
- Natural product screening
Molecular & Genetic Studies
- Gene expression profiling
- Protein-protein interaction networks
- DNA damage and repair mechanisms
- Epigenetic regulation in disease
Bioinformatics & Data Science
- Multi-omics data integration
- Machine learning for biological prediction
- Pathway and network analysis
- Computational toxicology
Advanced Experimental Methods
- Microfluidic technologies
- Optogenetics and electrophysiology
- Advanced imaging modalities
- Stem cell-based models
Emerging Research Frontiers
Tier 3: Selective Consideration- Artificial intelligence and deep learning in biomolecular prediction
- Quantum computing applications in drug discovery
- Single-cell multi-omics for drug response profiling
- CRISPR-based therapeutic screening platforms
- Organoid models for personalized medicine
- Microbiome-drug interaction modeling
Editorial Note: Manuscripts in emerging areas undergo additional editorial review to ensure methodological rigor and alignment with journal scope. Preliminary or proof-of-concept studies must demonstrate clear translational potential.
Explicitly Out of Scope
Not Considered- Reproductive technologies and fertility treatments Rationale: IVF, embryo transfer, and assisted reproduction fall outside pharmaceutical sciences and drug development focus.
- Standalone clinical trials without mechanistic investigation Rationale: Clinical-only studies lack the experimental or computational integration central to journal mission.
- Food chemistry and nutritional science Rationale: Unless directly related to drug-nutrient interactions or pharmacological compounds, food science is out of scope.
- Purely theoretical models without experimental validation Rationale: Computational predictions must be supported by in-vitro or in-vivo data to demonstrate biological relevance.
- Observational epidemiology or population health studies Rationale: Descriptive studies without experimental drug development components do not align with journal focus.
Article Types & Editorial Priorities
Fast-Track
Priority 1
- Original Research Articles
- Systematic Reviews & Meta-Analyses
- Methods & Protocols
- Validation Studies
Standard
Priority 2
- Short Communications
- Data Notes & Resources
- Perspectives & Commentaries
- Technical Notes
Selective
Rarely Considered
- Case Reports (only with novel mechanistic insights)
- Opinion Pieces (by invitation)
- Letters to Editor
Editorial Standards & Requirements
Reporting Guidelines
ARRIVE for animal studies, CONSORT for trials, PRISMA for reviews, MIAME for microarray data
Data Transparency
Raw data deposition in public repositories required; code availability for computational studies
Ethics Compliance
IRB/IACUC approval mandatory; adherence to Declaration of Helsinki and 3Rs principles
Preprint Policy
Preprints accepted; authors must disclose preprint DOI at submission
Publication Metrics
21
Days to First Decision
35%
Acceptance Rate
45
Days to Publication
Open
Access Model
Ready to Submit?
If your research integrates in-vitro, in-vivo, and in-silico approaches to advance pharmaceutical sciences, we invite your submission. For scope inquiries, contact our editorial team.
Contact Editorial Office
